Patents Assigned to Hoffmann-La Roche Inc.
  • Publication number: 20190177329
    Abstract: The present invention relates to a compound of formula I wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, —CH2—C3-6-cycloalkyl or bridged C4-6-cycloalkyl, substituted by one, two or three halogen atoms, or by lower alkyl or lower alkyl substituted by halogen; R2 is a five or six membered heteroaryl group, selected from wherein R6 is hydrogen, lower alkyl, halogen or lower alkoxy; and R7 is hydrogen, lower alkoxy or halogen; R3 is lower alkyl or lower alkyl substituted by hydroxy: R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; n is 1 or 2; -( )n- is —CH2— or —CH2CH2— for n being 1 or 2; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
    Type: Application
    Filed: January 10, 2019
    Publication date: June 13, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Hasane Ratni, Michael Reutlinger, Sandra Steiner
  • Patent number: 10316036
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Patent number: 10316059
    Abstract: The present invention is directed to methods comprising the use of hydroxyapatite chromatography to separate a bispecific antibody from a solution that also comprises one or more byproducts specific to bispecific antibody production. Byproducts specific to the production of bispecific antibodies (bispecific antibody specific byproducts, “BASB”) include fragments of the bispecific antibody and heavier molecular weight variants of the antibody, wherein the fragment and/or variant comprises an Fc domain but does not exhibit affinity for the two different epitopes and/or antigens as exhibited by the desired bispecific antibody. Thus, the methods of the present invention comprise the separation of a bispecific antibody from one or more of its BASB. The hydroxyapatite chromatography methods of the invention may be used alone or may be further combined with standard purification processes and unit operations as is known in the art to achieve any level of purity of bispecific antibody necessary, e.g.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Bertl, Harald Duerr, Andreas Schaubmar
  • Patent number: 10316082
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Publication number: 20190169277
    Abstract: The present invention relates to improved antibodies specific for Tenascin-C (TnC), in particular domain specific anti-TnC antibodies with improved cross-species reactivity. In addition, the invention relates to polynuleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies and methods of using them in the treatment of disease.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ralf HOSSE, Ekkehard MOESSNER, Pablo UMANA
  • Publication number: 20190168177
    Abstract: The present patent application describes a stirrer comprising a combination of at least one axially-conveying element and at least one radially-conveying element relative to the rotary shaft of the stirrer wherein the largest diameter of the at least one axially-conveying element is equal to or less than the inner diameter di of the radially-conveying element. In one embodiment the stirrer according to the invention is a combination of one anchor stirrer with at least one inclined-blade stirrer. Furthermore the use of the stirrer according to the invention for the culture of cells in a dialysis method is described.
    Type: Application
    Filed: August 14, 2018
    Publication date: June 6, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Marco JENZSCH, Max LECHNER, Michael POHLSCHEIDT, Christoph REESE, Alexander SCHOLZ, Hermann TEBBE
  • Publication number: 20190169222
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 2, 2018
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20190169189
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: BERND BUETTELMANN, BUELENT KOCER, BERND KUHN, MARCO PRUNOTTO, HANS RICHTER, MARTIN RITTER, MARKUS RUDOLPH, ALEXANDER LEE SATZ
  • Patent number: 10308710
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Patent number: 10308659
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier Gavelle, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Roever Stephan, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • Publication number: 20190153071
    Abstract: The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same.
    Type: Application
    Filed: November 26, 2018
    Publication date: May 23, 2019
    Applicant: HOFFMANN-LA ROCHE, INC.
    Inventors: Christian KLEIN, Wolfgang SCHAEFER
  • Publication number: 20190153091
    Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.
    Type: Application
    Filed: October 3, 2018
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
  • Publication number: 20190153491
    Abstract: The present invention relates to the use of a protein as a hydroxylase, a host cell comprising the protein, the use of the protein or host cell in the production of hydroxy-pipecolic acid (HPA), a method of production HPA, methods of producing the protein, a mutant protein and a nucleic acid encoding the mutant protein and a vector comprising a nucleic acid encoding the protein.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mara Boenitz-Dulat, Hans Iding, Dennis Wetzl, Alessa Hinzmann
  • Publication number: 20190152895
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10 and R11 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans P. MAERKI, Benoit HORNSPERGER, Peter MOHR, Michael REUTLINGER, Markus RUDOLPH
  • Publication number: 20190154664
    Abstract: This patent application relates to a method for determining the in vitro efficacy profile of a drug candidate using standardized cell cultures of uniformly distributed differentiated neural cells (NCs) from at least two primate species, wherein the differentiated NC cultures are qualified for high throughput screening based on a dissociation and reseeding step performed on the differentiated NCs. The method includes differentiating human and/or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) followed by dissociating the differentiated NCs from its support and reseeding the differentiated NCs in a high-throughput cell culture format resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Carlo CUSULIN, Veronica COSTA, Marius HOENER, Christoph PATSCH, Eva Christina THOMA
  • Publication number: 20190156510
    Abstract: An image analysis method for analyzing an IHC tissue sample includes storing, for each of one or more sets of digital images, a set-ID in a spatial database of a spatial DBMS, the images of each set depicting the same or adjacent layers of the IHC tissue sample; storing, for each of the, a plurality of spatial data objects in the database in association with the set-ID; creating, by the spatial DBMS, at least one spatial index covering the objects of the images contained in the one or more sets; applying, by the spatial DBMS, a spatial database operation on the at least one spatial index for determining the relative positions of objects of two or more images of a selected set; and providing the relative positions as input for determining the distance and/or relative position of the biomedical features of the tissue sample.
    Type: Application
    Filed: March 2, 2017
    Publication date: May 23, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Franziska MECH, Angelika FUCHS, Jan KUENTZER, Otto HUBER, Alex KOHN, Eckhart GUTHOEHRLEIN
  • Publication number: 20190151290
    Abstract: The present invention relates to the use of aleglitazar in the treatment or prevention of diabetic kidney disease in a patient having a linear decline in GFR.
    Type: Application
    Filed: September 12, 2018
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Regina DUTTLINGER MADDUX, Carl Anders SVENSSON, Jin TIAN, Harold V. BARRON
  • Publication number: 20190144457
    Abstract: Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Holger Kuehne, Patrizio Mattei, Markus Rudolph
  • Publication number: 20190144458
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: BARBARA BIEMANS, GEORG JAESCHKE, ANTONIO RICCI, DANIEL RUEHER, FIONN O'HARA
  • Publication number: 20190144468
    Abstract: The present invention relates to a process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pascal DOTT, Fabian FEYEN, Stefan HILDBRAND, Ursula HOFFMANN, Fabienne HOFFMANN-EMERY, Roland MEIER, Gerard MOINE, Pankaj REGE, Georg WUITSCHIK